Business Wire

Due to Overwhelming Demand, Velodyne Lidar LIVE! Adds New Host and Episodes

Share

Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) today announced new episodes of its digital learning series Velodyne Lidar LIVE! and addition of a second host, auto industry expert Charlie Vogelheim, to expand the series with a wider variety of featured guests and new formats. The series is moving to two episodes per month to meet audience demand to explore the many ways autonomous solutions are advancing safe mobility and smart communities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210601005157/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Velodyne Lidar announced new episodes of its digital learning series Velodyne Lidar LIVE! The June 4 episode will feature Kat Dransfield, Vice President, Product and Digital Platform Strategy at Local Motors. Dransfield will discuss global deployment of the Olli 2.0 self-driving vehicle and building next-generation 3D-printed vehicles at the Local Motors microfactory in Knoxville, Tenn. (Photo: Velodyne Lidar)

To register for episodes of the free Velodyne Lidar LIVE! webinar series visit: https://velodynelidar.com/events/.

The 45-minute webinars feature conversations with industry experts that are shaping future mobility, which will transform lives, communities and industries. Previous episodes have looked at test driving connected and automated vehicles, and how autonomous solutions can improve traffic monitoring, mobile mapping and baggage handling at airports. New formats include panel discussions to help episodes go deeper into topics.

Experts speaking on future episodes include:

  • June 4, 2021 at 10:00 a.m. PDT: Kat Dransfield, Vice President, Product and Digital Platform Strategy at Local Motors. Dransfield will discuss global deployment of the Olli 2.0 self-driving vehicle and building next-generation 3D-printed vehicles at the Local Motors microfactory in Knoxville, Tenn.
  • July 9, 2021 at 10 a.m. PDT: Kamil Litman, Vice President of Software, May Mobility. Litman will explore how safe, efficient and sustainable shuttle solutions can complement public transportation options.
  • August 6, 2021 at 10 a.m. PDT: Sameer Sharma, Global GM (Smart Cities & Transportation), IOT Solutions, Intel and Jon Barad, Velodyne’s Vice President of Business Development. This discussion will explore policy and regulation around intelligent infrastructure, as well as how smart city applications can improve public services and enhance safety and quality of life.
  • August 20, 2021 at 10 a.m. PDT: Natasha Thomas, MNM, Executive Director, Mothers Against Drunk Driving Northern California. Thomas will address the role of autonomous vehicle technology in moving towards the goal of zero deaths caused by drunk driving.

Charlie Vogelheim joins Pamela Gauci, Velodyne’s Director, Events and Marketing, as series host. Vogelheim has over 30 years of automotive industry experience including as host of Motor Trend Audio, executive editor at Kelley Blue Book and Vice President at J.D. Power and Associates. He received widespread acclaim for his role as moderator of the 2020 World Safety Summit.

“Our audience has told us they want to learn more about how autonomy is bringing safe, sustainable and accessible transportation and smart communities,” said Sally Frykman, Chief Marketing Officer, Velodyne Lidar. “There is a great diversity in applications that have been deployed with lidar solutions. Velodyne Lidar LIVE! will continue to showcase the many autonomous solutions in action today that are touching lives in meaningful ways around the world.”

About Velodyne Lidar

Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne, the global leader in lidar, is known for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com.

Forward Looking Statements

This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, and competition. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," “can,” "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; uncertainties regarding government regulation and adoption of lidar; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Velodyne Investor Relations
InvestorRelations@velodyne.com

Media
Liv Allen
(415) 370-0716
velodyne@codewordagency.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release

I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye